Evidence map›Paper›PMID 31761718›Full record

ArticleCell host & microbe2019

Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread.

Jason M Hataye, Joseph P Casazza, Katharine Best, C Jason Liang, Taina T Immonen, David R Ambrozak, Samuel Darko, Amy R Henry, Farida Laboune, Frank Maldarelli and 6 more

Abstract read
In one paragraph

Article in Cell host & microbe, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Jason M HatayeImmunology Section, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. Electronic address: jason.hataye@nih.gov.
Joseph P CasazzaImmunology Section, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Katharine BestTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
C Jason LiangBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD 20892, USA.
Taina T ImmonenAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
David R AmbrozakImmunology Section, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Samuel DarkoHuman Immunology Section, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Amy R HenryHuman Immunology Section, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Farida LabouneHuman Immunology Section, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Frank MaldarelliHIV Dynamics and Replication Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Daniel C DouekHuman Immunology Section, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Nicolas W HengartnerTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Takuya YamamotoLaboratory of Immunosenescence, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka 567-0085, Japan.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Alan S PerelsonTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Richard A KoupImmunology Section, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. Electronic address: rkoup@mail.nih.gov.

Funding

Viral dynamics of rebound and control following early treatment of HIV/SIVP01AI131365 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2017 to 2021
$7.5M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 AI999999NCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI131365NIAID NIH HHS R01 AI028433NIH HHS R01 OD011095
6 · The paper itself

Abstract

A population at low census might go extinct or instead transition into exponential growth to become firmly established. Whether this pivotal event occurs for a within-host pathogen can be the difference between health and illness. Here, we define the principles governing whether HIV-1 spread among cells fails or becomes established by coupling stochastic modeling with laboratory experiments. Following ex vivo activation of latently infected CD4 T cells without de novo infection, stochastic cell division and death contributes to high variability in the magnitude of initial virus release. Transition to exponential HIV-1 spread often fails due to release of an insufficient amount of replication-competent virus. Establishment of exponential growth occurs when virus produced from multiple infected cells exceeds a critical population size. We quantitatively define the crucial transition to exponential viral spread. Thwarting this process would prevent HIV transmission or rebound from the latent reservoir.

Indexed as

HIV-1CD4-Positive T-LymphocytesHIV InfectionsHumansModels, BiologicalPopulation DynamicsViral LoadVirus ActivationVirus LatencyVirus ReplicationAllee effectcritical thresholdexponential growthHIVlatencylatent reservoirmathematical modelingpopulation dynamicsreboundviral dynamics

Identifiers

PMID31761718
PMCPMC6948011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.